Authors
Yi Luo, Xijie Wu, Wenjing Chen, Ziao He, Yan Yang, Linjie Ma, Hongqiang Chen, Sicheng Zhang, Chao Li
Published in
Frontiers in pharmacology. Volume 17. Pages 1794285. Epub Apr 01, 2026.
Abstract
Oral cancer remains a major global health burden. Current therapies are often limited by recurrence, drug resistance, and systemic toxicity. Natural bioactive metabolites, particularly those derived from medicinal plants used in Traditional Chinese Medicine are increasingly investigated as multitarget anticancer leads. In this review, we integrated evidence from studies published between January 2010 and June 2025. We summarize representative flavonoids, terpenoids, phenolic metabolites, alkaloids, polysaccharides, and quinones evaluated in oral cancer models. Reported activities include suppression of proliferation, induction of apoptosis and autophagy, inhibition of epithelial-mesenchymal transition and angiogenesis, and modulation of tumor metabolism and immune pathways. However, the current evidence base remains largely preclinical and frequently relies on simplified in vitro assays. Pharmacokinetic bridging, toxicity evaluation, and clinically relevant validation are still limited. Importantly, several polyphenolic metabolites exhibit pan-assay interference (PAINS) liabilities, requiring cautious interpretation of pathway-level findings. Advances in nano-delivery systems, rational structural optimization, and combination strategies may improve exposure and selectivity. Future work should emphasize PAINS-aware pharmacological rigor, orthogonal target validation, advanced translational models, and biomarker-driven clinical trials to support the development of genuinely druggable natural metabolite candidates for oral cancer management.
PMID:
41993589
Bibliographic data and abstract were imported from PubMed on 01 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 16
- Comments 0